RTP Mobile Logo
What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Multiple Myeloma (Webinar Video Proceedings)
Released January 2022

Featuring perspectives from Drs Larry Anderson Jr, Morie Gertz, Irene Ghobrial and Peter Voorhees, moderated by Dr Robert Orlowski. Published January 24, 2022. (Webinar Video Proceedings)

CE Disclosures and Faculty Information

    This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of multiple myeloma.


    • Customize the use of induction, consolidation and maintenance therapeutic approaches for multiple myeloma (MM) in transplant and nontransplant settings, considering patient- and disease-related factors including cytogenetic profile.
    • Appreciate clinical trial data informing the use of monoclonal antibody therapy directed at CD38 for patients with newly diagnosed and relapsed/refractory (R/R) MM, and effectively identify when and how these agents should be integrated into clinical management.
    • Consider published research findings and other clinical factors in the best-practice selection, sequencing and combining of established regimens in the care of patients with R/R MM.
    • Develop an understanding of the mechanisms of action of and pivotal clinical trial findings with recently FDA-approved novel therapies (eg, isatuximab, selinexor, belantamab mafodotin) to facilitate their integration into MM management algorithms.
    • Evaluate the biologic rationale for the use of chimeric antigen receptor T-cell therapy directed at B-cell maturation antigen as a targeted therapeutic strategy for MM, and identify patients for whom treatment with this novel approach should be considered.
    • Recall the design of ongoing clinical trials evaluating novel agents and strategies for MM, and counsel appropriate patients about availability and participation.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    Research To Practice designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of these CME activities, which includes participation in the evaluation components and short post-tests, enables the participant to earn up to 2.25 (Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 100% and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ASH2021/MM/CME.

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY AND MODERATOR — The following faculty reported relevant financial relationships with ineligible entities:

    Larry D Anderson Jr, MD, PhD
    Associate Professor
    Director of Myeloma, Waldenström’s, and Amyloidosis Program
    UT Southwestern Medical Center
    Simmons Comprehensive Cancer Center
    Dallas, Texas

    Advisory Committee, Consulting Agreements and Contracted Research: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline, Janssen Biotech Inc, Karyopharm Therapeutics, Oncopeptides; Data and Safety Monitoring Board/Committee: Prothena.

    Morie A Gertz, MD, MACP
    Consultant, Hematology
    Mayo Clinic
    Rochester, Minnesota

    Advisory Board: Ionis Pharmaceuticals; Consulting Agreements: Akcea Therapeutics, Alnylam Pharmaceuticals Inc, Prothena; Data and Safety Monitoring Board/Committee: AbbVie Inc, Celgene Corporation; Honoraria: Akcea Therapeutics, Ambry Genetics, Amgen Inc, Celgene Corporation, Janssen Biotech Inc, Karyopharm Therapeutics, Pfizer Inc (to Institution), Sanofi Genzyme; Stock Options: Aurora Biopharma.

    Irene M Ghobrial, MD
    Professor of Medicine
    Lavine Family Chair of Preventative Cancer Therapies
    Director, Center for Prevention of Progression of Blood Cancers
    Director, Translational Research in Multiple Myeloma
    Director, Clinical Investigator Research Program
    Director, Michele and Steven Kirsch Laboratory
    Harvard Medical School
    Dana-Farber Cancer Institute
    Boston, Massachusetts

    Advisory Committee: Amgen Inc (Europe), Aptitude Health, Bristol-Myers Squibb Company, GlaxoSmithKline, GNS Healthcare, Janssen Biotech Inc, Mind Wrap Medical LLC, Pfizer Inc, Sanofi Genzyme, Takeda Pharmaceuticals USA Inc; Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, Amgen Inc (Europe), Aptitude Health, Binding Site, Bristol-Myers Squibb Company, Celgene Corporation, Cellectar Biosciences Inc, CohBar, Curio Science, DAVA Oncology, Genentech, a member of the Roche Group, GlaxoSmithKline, GNS Healthcare, Huron, Janssen Biotech Inc, Janssen Central America and Caribbean, Karyopharm Therapeutics, Magenta Therapeutics, Menarini Silicon Biosystems, Mind Wrap Medical LLC, Multiple Myeloma Research Foundation, Oncopeptides, Pfizer Inc, PureTech Health, Sanofi Genzyme, Sognef, Takeda Pharmaceuticals USA Inc; Contracted Research: Bristol-Myers Squibb Company, Janssen Biotech Inc, Takeda Pharmaceuticals USA Inc; Spouse: CMO and equity holder of Disc Medicine (private company, not publicly traded).

    Peter Voorhees, MD
    Professor of Medicine
    Chief, Plasma Cell Disorders Division
    Director of Medical Operations and Outreach Services
    Department of Hematologic Oncology and Blood Disorders
    Levine Cancer Institute, Atrium Health
    Charlotte, North Carolina

    Advisory Committee: AbbVie Inc, Bristol-Myers Squibb Company, GlaxoSmithKline, Karyopharm Therapeutics, Pfizer Inc, Sanofi Genzyme; Consulting Agreements: Amgen Inc, Secura Bio; Data and Safety Monitoring Board/Committee: Bristol-Myers Squibb Company, Karyopharm Therapeutics.


    Robert Z Orlowski, MD, PhD
    Florence Maude Thomas Cancer Research Professor
    Department of Lymphoma and Myeloma
    Professor, Department of Experimental Therapeutics
    Director, Myeloma Section
    Division of Cancer Medicine
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Advisory Committee: Amgen Inc, BioTheryX Inc, Bristol-Myers Squibb Company, GlaxoSmithKline, Janssen Biotech Inc, Karyopharm Therapeutics, Neoleukin Therapeutics, Oncopeptides, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Servier Pharmaceuticals LLC, Takeda Pharmaceuticals USA Inc; Clinical Research: CARsgen Therapeutics, Celgene Corporation, Exelixis Inc, Janssen Biotech Inc, Sanofi Genzyme, Takeda Pharmaceuticals USA Inc; Laboratory Research: BioTheryX Inc, Heidelberg Pharma, Pfizer Inc; Ownership Interest: Asylia Therapeutics Inc (founder with equity interest and director, scientific advisory board).

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    TThis activity is supported by educational grants from Bristol-Myers Squibb Company, GlaxoSmithKline, Karyopharm Therapeutics, Oncopeptides and Sanofi Genzyme.

    Release date: January 2022
    Expiration date: January 2023

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):